New federal rule will end Medicaid and CHIP funding for gender-affirming treatments for minors, while the administration says the move is intended to protect children
Summary
The Trump administration has finalized a new federal policy that will prevent Medicaid and the Children’s Health Insurance Program (CHIP) from using federal funds to pay for gender-affirming medical care for minors. The rule covers puberty blockers, hormone therapy and gender-affirming surgeries, although such surgeries are rare among minors. The administration says the policy is intended to protect children from what it considers potentially harmful and irreversible treatments. Medical groups and LGBTQ+ advocates strongly disagree, arguing that decisions about gender-affirming care should be made by patients, parents and medical professionals based on individual circumstances. The rule is scheduled to take effect on October 13, 2026, and legal challenges are expected.
A Major Change to Medicaid Coverage
President Donald Trump’s administration has taken another significant step in its effort to restrict gender-affirming care for transgender young people.
Under the rule finalized by the administration, states will no longer be able to receive federal Medicaid or CHIP funding for specified gender-affirming treatments provided to minors. The policy includes puberty blockers, hormone treatments and surgeries. It is scheduled to take effect in October.
The decision represents a change in how federal health programs can be used to pay for these services. It does not, by itself, make every form of gender-affirming treatment illegal across the United States. States may still face different rules depending on their own laws and policies.
That distinction matters because the debate surrounding the announcement has sometimes blurred the difference between restricting federal funding and banning medical treatment altogether.
Why the Trump Administration Says It Is Necessary
The administration has presented the policy as a child-protection measure.
Trump officials argue that minors should not be exposed to medical interventions that they describe as potentially irreversible or harmful. The administration has also pointed to concerns about the quality and long-term evidence surrounding some treatments for young people.
The Centers for Medicare & Medicaid Services has said the policy is intended to prevent federal taxpayer dollars from being used for what the administration calls “sex-rejecting procedures.” The administration estimates that the measure could save about $235 million over a decade.
The policy follows a broader effort by Trump since returning to office to change federal policy on transgender healthcare. In January 2025, Trump issued an executive order directing federal agencies to take steps to end what his administration described as the use of harmful medical interventions on children.
The Surgery Debate Is More Complicated
One of the most important points in the debate is the role of surgery.
Public discussion about transgender healthcare involving children often focuses heavily on gender-affirming surgery. In reality, research has found that such procedures are rare among minors.
FactCheck.org, citing research from Harvard researchers, reported that gender-affirming surgeries among minors are uncommon and that procedures involving younger children are particularly rare. A study of insured patients found no gender-affirming surgeries among transgender and gender-diverse children under 12 in 2019, while surgeries among older minors were rare and largely involved chest procedures.
That means the new Medicaid policy is broader than simply stopping federal funding for surgery.
It also covers medications, including puberty blockers and hormone therapy, which are much more relevant to the number of young people receiving medical gender-affirming care.
Medical Groups Push Back
The administration’s position has been strongly challenged by medical organisations and advocates.
The American Academy of Pediatrics, the American Medical Association and other professional organisations have supported access to gender-affirming care under appropriate medical guidance, although the evidence and recommendations surrounding treatment for young people have been the subject of continuing debate.
Critics of the Trump administration’s rule argue that the federal government is interfering with decisions that should be made by families and healthcare professionals. They also warn that removing federal funding could make treatment less accessible for low-income families.
More than 90% of public comments submitted during the rule-making process opposed the change, according to Reuters. Democratic state attorneys general have also challenged the policy in court.
What Happens to Children Already Receiving Treatment?
The new policy does not simply mean that every treatment stops immediately.
According to the administration’s rule, there will be a transition period for some young people already receiving hormone therapy. Existing treatment can continue to receive federal funding for a limited period before the new restrictions fully apply.
Mental health services related to gender dysphoria will also remain covered under Medicaid, according to reporting on the rule.
That distinction could become important for families trying to understand what the new policy actually means for their children.
A Broader Political Fight
The Medicaid decision is part of a much larger political battle over transgender rights in the United States.
Since returning to the White House, Trump has made restrictions on transgender healthcare one of the administration’s policy priorities. His administration has also pursued changes involving federal healthcare programmes, hospitals, military policy and other areas affecting transgender Americans.
The issue has become particularly contentious because it combines questions about healthcare, parental authority, federal spending and the rights of transgender people.
For supporters of the new rule, the central issue is whether taxpayers should be required to finance treatments they believe carry unacceptable risks for minors.
For opponents, the question is whether the federal government should be deciding which medically supervised treatments families can access through public insurance.
The Rule Could Face a Long Legal Battle
The policy is unlikely to settle the debate on its own.
Legal challenges are expected, and the outcome could determine how much authority the federal government has to restrict Medicaid funding for particular categories of medical care.
There is also an important federal-state issue. Medicaid is jointly funded and administered by the federal government and the states. While Washington controls the federal share of funding, states have their own laws and policies governing healthcare.
As a result, the practical impact of the rule could vary across the country.
Some states may choose to use their own funds to continue covering certain services, while others may already have restrictions in place.
Conclusion
So, did President Donald Trump “save children” through the new Medicaid restrictions?
That depends largely on how the policy is viewed.
The Trump administration says it is protecting young people from medical treatments it considers harmful and ensuring that federal taxpayer money is not used for such care. Medical organisations and LGBTQ+ advocates argue that the policy instead limits access to healthcare that can be appropriate for some transgender young people when provided under medical supervision.
What is clear is that the policy is broader than gender-affirming surgery alone. It affects federal Medicaid and CHIP funding for puberty blockers, hormone therapy and specified surgeries for minors, while mental health services remain covered. The rule is set to take effect in October and is likely to face legal challenges before its long-term impact becomes clear.
For families, the biggest question is no longer simply whether gender-affirming care is legal. It is whether they will be able to afford it, where they live, and what happens to federal and state funding as the new policy moves through the courts.
CK SHARMA Editor In Chief Toronto